| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae0412e72f24b7aea064b1505c6cc11c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2005-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ab8d0343040658570e77ec62f521176
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e4a8a785bc62e6316f3583b63960793
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f278d57e6d86afabb0200b021f18fcf6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5aa9836e00a51c39d6ed4f680d5bb21 |
| publicationDate |
2011-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7960109-B2 |
| titleOfInvention |
mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer |
| abstract |
Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and PSA expression in a urine sample and (b) correlating the value of the PCA3/PSA ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of PSA in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of PSA; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8772459-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9951390-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10517969-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9096907-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11105808-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012003640-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8257924-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11180570-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11421282-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009226912-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8940298-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8951737-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9732389-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9534256-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10443105-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11266745-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9527919-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11254744-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8940871-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10752957-B2 |
| priorityDate |
2004-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |